The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI b...

Full description

Saved in:
Bibliographic Details
Published in:Asia Pac J Clin Oncol
Main Authors: Sakata, Yoshihiko, Kawamura, Kodai, Shingu, Naoki, Hiroshige, Shigeo, Yasuda, Yuko, Eguchi, Yoshitomo, Anan, Keisuke, Hisanaga, Junpei, Nitawaki, Tatsuya, Nakano, Aiko, Ichikado, Kazuya
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379949/
https://ncbi.nlm.nih.gov/pubmed/30506897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13103
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items